- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 24.10. | IMPEDIMED LIMITED: Q1 FY26 results webinar & launch of Impedimed Investor Hub | - | ASX | ||
| IMPEDIMED Aktie jetzt für 0€ handeln | |||||
| 23.10. | IMPEDIMED LIMITED: Notification regarding FY26 Non-executive Director fees | - | ASX | ||
| 21.10. | IMPEDIMED LIMITED: Investor Presentation - Canaccord Drug and Device Conference | - | ASX | ||
| 16.10. | IMPEDIMED LIMITED: Online Meeting Guide | - | ASX | ||
| 16.10. | IMPEDIMED LIMITED: Notice of Annual General Meeting & Voting Form | - | ASX | ||
| 13.10. | IMPEDIMED LIMITED: Notification of cessation of securities - IPD | - | ASX | ||
| 13.10. | IMPEDIMED LIMITED: Notification regarding unquoted securities - IPD | - | ASX | ||
| 02.10. | IMPEDIMED LIMITED: Major US health insurer publishes positive coverage | - | ASX | ||
| 19.09. | IMPEDIMED LIMITED: Date of Annual General Meeting | - | ASX | ||
| 04.09. | IMPEDIMED LIMITED: Application for quotation of securities - IPD | 2 | ASX | ||
| 01.08. | IMPEDIMED LIMITED: Change of Director's Interest Notice - Mr Andrew Grant | - | ASX | ||
| 01.08. | IMPEDIMED LIMITED: Change of Director's Interest Notice-Ms Emmanuel-Donnelly | - | ASX | ||
| 01.08. | IMPEDIMED LIMITED: Change of Director's Interest Notice - Ms Janelle Delaney | - | ASX | ||
| 01.08. | IMPEDIMED LIMITED: Change of Director's Interest Notice - Ms Fiona Bones | - | ASX | ||
| 31.07. | IMPEDIMED LIMITED: Application for quotation of securities - IPD | - | ASX | ||
| 31.07. | IMPEDIMED LIMITED: Application for quotation of securities - IPD | - | ASX | ||
| 31.07. | IMPEDIMED LIMITED: Quarterly Activities Report and Appendix 4C - Jun-2025 Qtr | - | ASX | ||
| 31.07. | IMPEDIMED LIMITED: Investor Presentation | - | ASX | ||
| 29.07. | IMPEDIMED LIMITED: Notification regarding unquoted securities - IPD | - | ASX | ||
| 16.07. | IMPEDIMED LIMITED: Notification of Quarterly Results & Investor Conference Call | - | ASX |
1 2 Weiter >>
24 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| ALIGNMENT HEALTHCARE | 16,870 | -1,75 % | Alignment Healthcare Reports Third Quarter 2025 Results, Surpasses High-End of Guidance Across All Key Metrics | Reports Q3 revenue of $993.7 million, up 43.5% year-over-yearBeats high end of third quarter guidance and raises full-year outlook across all key metrics: membership, revenue, adjusted gross profit... ► Artikel lesen | |
| BRIGHTSPRING HEALTH SERVICES | 33,040 | +0,76 % | BrightSpring Health Services GAAP EPS of $0.17 misses by $0.15, revenue of $3.33B misses by $20M | ||
| SIEMENS HEALTHINEERS | 48,680 | +0,23 % | EQS-CMS: Siemens Healthineers AG: Veröffentlichung einer Kapitalmarktinformation | EQS Zulassungsfolgepflichtmitteilung: Siemens Healthineers AG
/ Bekanntmachung nach Art. 5 Abs. 1 lit. b), Abs. 3 der Verordnung (EU) Nr. 596/2014, zuletzt geändert durch die Verordnung... ► Artikel lesen | |
| FRESENIUS | 49,880 | -0,28 % | DEUTSCHE BANK RESEARCH stuft Fresenius SE auf 'Buy' | FRANKFURT (dpa-AFX Analyser) - Deutsche Bank Research hat das Kursziel für Fresenius von 52 auf 53 Euro angehoben und die Einstufung auf "Buy" belassen. Die anstehenden Quartalszahlen des Medizinkonzerns... ► Artikel lesen | |
| FRESENIUS MEDICAL CARE | 46,470 | -0,19 % | EQS-CMS: Fresenius Medical Care AG: Veröffentlichung einer Kapitalmarktinformation | EQS Zulassungsfolgepflichtmitteilung: Fresenius Medical Care AG
/ Bekanntmachung nach Art. 5 Abs. 1 lit. b) der Verordnung (EU) Nr. 596/2014
Fresenius Medical Care AG: Veröffentlichung... ► Artikel lesen | |
| GENEDX | 137,17 | +4,20 % | GeneDx raises 2025 revenue guidance to $428M amid accelerating exome and genome test growth | ||
| BUTTERFLY NETWORK | 2,695 | +31,78 % | Butterfly Network reaffirms $91M-$95M 2025 revenue target while accelerating AI and chip innovation | ||
| PROCEPT BIOROBOTICS | 34,040 | -1,02 % | PROCEPT BioRobotics Reports Second Quarter 2025 Financial Results and Increases 2025 Revenue Guidance | SAN JOSE, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (Nasdaq: PRCT) (the "Company"), a surgical robotics company focused on advancing patient care by developing transformative... ► Artikel lesen | |
| GERRESHEIMER | 27,460 | -0,51 % | Gerresheimer: Weitere Details - millionenschwere Fehlbuchung | Am Wochenende hat der Spezialverpackungshersteller Gerresheimer per Ad-Hoc-Mitteilung dem Kapitalmarkt weitere Details zur laufenden Prüfung problematischer Buchungen im Konzernbericht für das Fiskaljahr... ► Artikel lesen | |
| BETA BIONICS | 27,210 | +1,61 % | Beta Bionics, Inc.: Beta Bionics Reports Third Quarter 2025 Financial Results and Raises Full Year 2025 Guidance | IRVINE, Calif., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today reported its financial... ► Artikel lesen | |
| PROGYNY | 18,690 | +0,27 % | Progyny, Inc.: Progyny Expands Global Benefits to Include Pregnancy, Postpartum, and Menopause | Global employers can now empower their workforces with comprehensive women's health benefits, supported by localized expertiseNEW YORK, Oct. 22, 2025. (Nasdaq: PGNY), a global leader in women's health... ► Artikel lesen | |
| CLEARPOINT NEURO | 23,230 | -1,90 % | ClearPoint Neuro, Inc.: ClearPoint Neuro Announces Promising Results from Brain Tumor Laser Therapy Study to be Presented at the CNS Annual Meeting in Los Angeles | SOLANA BEACH, CALIFORNIA / ACCESS Newswire / October 7, 2025 / ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation... ► Artikel lesen | |
| PRIVIA HEALTH GROUP | 24,280 | -0,94 % | Privia Health Group, Inc. - 8-K, Current Report | ||
| GOODRX | 3,355 | -2,19 % | GoodRx Stock Could Get a Major Trump Boost. Should You Buy It Here? | ||
| TALKSPACE | 3,240 | +11,72 % | Talkspace sees big opportunities to lead AI in mental health as chatbots draw scrutiny |
IMPEDIMED LIMITED gehört der Branche Gesundheitswesen an. Die relative Kursveränderung beträgt aktuell -2,63 % bei einem Aktienkurs von 0,019 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu IMPEDIMED LIMITED finden Sie auf Wallstreet Online.